Imaged-based High-Throughput Screening for Anti-Angiogenic Drug Discovery

Title: Imaged-based High-Throughput Screening for Anti-Angiogenic Drug Discovery

Volume: 16 Issue: 35

Author(s): Lasse Evensen, Wolfgang Link and James B. Lorens

Affiliation:

Keywords: Angiogenesis, high-throughput screening, high-content imaging, HCS, HTS, PDGF, bevacizumab, fibroblast growth factor, Sunitinib, SU11248, Sorafenib, BAT43-9006, PTK787, ZK222584, Axitinib, AG013736, Vinblastine, Paclitaxel, Epothilones, tastatins, EC-vSMC, CAM, LOPAC1280, SU4312, Cognition Network, Technology (CNT), LOPAC

Abstract: Recent developments in high-content screening (HCS) technologies make it an attractive alternative for anti-angiogenic drug discovery. HCS integrates high-throughput methodologies with automated multicolor fluorescence microscopy to collect quantitative morphological and molecular data from complex biological systems. Organotypic systems based on primary vascular cells model many facets of angiogenesis. The adaptation of these complex in vitro assay systems to high-throughput HCS formats with automated image acquisition enables large-scale chemical library screening campaigns. These HCS principles can be extended further to allow small molecule compounds in in vivo model organisms such as zebrafish. In this review we discuss the latest developments within automated imagebased high-throughput screening of chemical libraries for anti-angiogenic compounds.

Cite this article as:

Evensen Lasse, Link Wolfgang and B. Lorens James, Imaged-based High-Throughput Screening for Anti-Angiogenic Drug Discovery, Current Pharmaceutical Design 2010; 16 (35) . https://dx.doi.org/10.2174/138161210794455030